Sept. 14, 2021– A new report issued by the Community Oncology Alliance (COA) claims 340B hospitals “charge both commercial payers and uninsured patients extraordinarily high prices and use an aggressive form of price discrimination between payers.” However, the report is highly flawed and presents an inaccurate picture of the role 340B plays in America’s health care safety … [Read more...]
Momentum Grows to End Medicare Cuts for 340B Hospitals
Sept. 9, 2021– Calls are increasing for the Biden administration to stop deep Medicare Part B payment cuts to many hospitals participating in the 340B drug pricing program. The reductions, which have been in place since January 2018, have been harmful for many safety-net hospitals and their patients. Earlier this summer, the administration issued proposed rules that would … [Read more...]
Merck Plan to Withhold 340B Discounts Adds to Threat to Diabetes Patients
August 26, 2021 - The global pharmaceutical manufacturer Merck is the latest company to announce it will stop offering 340B discounts to hospitals on drugs dispensed to patients at community pharmacies. The move comes three months after the federal government warned drug companies that such actions are unlawful under the 340B drug pricing program statute. Merck will become the … [Read more...]
Hope and Vigilance in the 340B Community
By Maureen Testoni August 9, 2021– From my perspective, last month’s 340B Coalition Summer Conference was notable for several reasons. The first was that it marked the 25th year of hosting the conference, reflecting on a quarter-century of work to ensure the 340B drug pricing program delivers on its benefits for safety-net hospitals, health centers, and clinics with a … [Read more...]
Bipartisan Congressional Calls to Protect 340B Intensify
Aug. 4, 2021– A pair of lawmakers is working to advance the latest example of bipartisan, pro-340B legislation in Congress. Reps. Abigail Spanberger (D-Va.) and David McKinley (R-W.V.) recently introduced the Preserving Rules Ordered for The Entities Covered Through 340B Act, also known as the PROTECT 340B Act, and are gathering cosponsors from both sides of the political … [Read more...]
Faces of 340B: Wellbeing and Peace of Mind
July 19, 2021– Despite lifelong health challenges, Chicago resident Tracy Kimble exudes a spirit of perseverance and independence. But there was a time in his life when Tracy felt the despair of being forced to choose between supporting his family and supporting his health. That’s when UI Health in Chicago and the 340B drug pricing program intervened to provide the assistance … [Read more...]
Boehringer Ingelheim Joins in the Attacks on 340B
July 12, 2021– The pharmaceutical giant Boehringer Ingelheim (BI), a manufacturer headquartered in Germany, is the latest company to announce it is cutting off discounts to safety-net hospitals participating in the 340B drug pricing program. If BI goes through with its threat on Aug. 1, it will become the seventh drug company to limit 340B discounts despite strong warnings by … [Read more...]